Abstract
Metastatic pancreatic cancer still represent one of the most deadly disease for which there are few therapeutic options, especially in second line and beyond setting. Nabpaclitaxel plus gemcitabine activity was demonstrated in first line setting, but there are no clear evidence suggesting its use after that. We report a retrospective data analysis of 23 patients who received nab-paclitaxel plus gemcitabine after first line treatment at our Oncology Department. We observed a significant clinical benefit (43,5%) with a median overall survival of 5 months. In addition, manageable side effects were reported. Our data, despite the small sample, seem to indicate that nab- paclitaxel plus gemcitabine is an active and well tolerated regimen even in pretreated patients.
Keywords: CA19.9, clinical benefit, gemcitabine, metastatic pancreatic cancer, nab- paclitaxel.
Reviews on Recent Clinical Trials
Title:Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis
Volume: 10 Issue: 2
Author(s): Paola Bertocchi, Chiara Abeni, Fausto Meriggi, Luigina Rota, Anna Rizzi, Brunella Di Biasi, Francesca Aroldi, Chiara Ogliosi, Giordano Savelli, Edoardo Rosso and Alberto Zaniboni
Affiliation:
Keywords: CA19.9, clinical benefit, gemcitabine, metastatic pancreatic cancer, nab- paclitaxel.
Abstract: Metastatic pancreatic cancer still represent one of the most deadly disease for which there are few therapeutic options, especially in second line and beyond setting. Nabpaclitaxel plus gemcitabine activity was demonstrated in first line setting, but there are no clear evidence suggesting its use after that. We report a retrospective data analysis of 23 patients who received nab-paclitaxel plus gemcitabine after first line treatment at our Oncology Department. We observed a significant clinical benefit (43,5%) with a median overall survival of 5 months. In addition, manageable side effects were reported. Our data, despite the small sample, seem to indicate that nab- paclitaxel plus gemcitabine is an active and well tolerated regimen even in pretreated patients.
Export Options
About this article
Cite this article as:
Bertocchi Paola, Abeni Chiara, Meriggi Fausto, Rota Luigina, Rizzi Anna, Di Biasi Brunella, Aroldi Francesca, Ogliosi Chiara, Savelli Giordano, Rosso Edoardo and Zaniboni Alberto, Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis, Reviews on Recent Clinical Trials 2015; 10 (2) . https://dx.doi.org/10.2174/1574887110666150417115303
DOI https://dx.doi.org/10.2174/1574887110666150417115303 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of New Pancreatic Beta Cell Targets for In Vivo Imaging by a Systems Biology Approach
Current Pharmaceutical Design Statins and Solid Organ Transplantation
Current Pharmaceutical Design α-Methylated Polyamines as Potential Drugs and Experimental Tools in Enzymology
Mini-Reviews in Medicinal Chemistry Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Adiposity and the Gut - The Role of Gut Hormones
Current Nutrition & Food Science Lectins in Human Cancer: Both a Devil and an Angel?
Current Protein & Peptide Science GLP-1 Agonists Exenatide and Liraglutide: A Review About Their Safety and Efficacy
Current Clinical Pharmacology Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science Structure-Based Design of Novel Anti-Cancer Agents TargetingAurora Kinases
Current Medicinal Chemistry - Anti-Cancer Agents Medium-term Culture of Normal Human Oral Mucosa: A Novel Three-dimensional Model to Study the Effectiveness of Drugs Administration
Current Pharmaceutical Design Energizing Genetics and Epi-genetics: Role in the Regulation of Mitochondrial Function
Current Genomics Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis
Current Medicinal Chemistry Anti-Cancer Phytometabolites Targeting Cancer Stem Cells
Current Genomics Lipid Mediator Profiling in Pulmonary Disease
Current Pharmaceutical Biotechnology Chronic Complications of Diabetes Mellitus: A Mini Review
Current Diabetes Reviews The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine A Survey on the Applications of Implantable Micropump Systems in Drug Delivery
Current Drug Delivery